| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hyperplasia | D006965 | 34 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Asthenia | D001247 | 5 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hamblett KJ et al. | AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. | 2015 | Mol. Cancer Ther. | pmid:25931519 |
| Ab O et al. | IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. | 2015 | Mol. Cancer Ther. | pmid:25904506 |
| Weiler D et al. | Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer. | 2015 | J Thorac Oncol | pmid:25789838 |
| Krop IE et al. | Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. | 2015 | J. Clin. Oncol. | pmid:25713436 |
| Marcoux J et al. | Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. | 2015 | Protein Sci. | pmid:25694334 |
| Goldmacher VS et al. | High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. | 2015 | PLoS ONE | pmid:25671541 |
| Nicoletti R et al. | T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. | 2015 | Clin. Exp. Metastasis | pmid:25398397 |
| Uppal H et al. | Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). | 2015 | Clin. Cancer Res. | pmid:25370470 |
| Krop IE et al. | Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. | 2015 | Ann. Oncol. | pmid:25355722 |
| Eisenstein M | Medicine: Eyes on the target. | 2015 | Nature | pmid:26580159 |
| Widdison WC et al. | Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing. | 2015 | Bioconjug. Chem. | pmid:26355774 |
| Cosmai L et al. | Renal toxicity of anticancer agents targeting HER2 and EGFR. | 2015 | J. Nephrol. | pmid:26341657 |
| Bartsch R et al. | Activity of T-DM1 in Her2-positive breast cancer brain metastases. | 2015 | Clin. Exp. Metastasis | pmid:26303828 |
| Michel LL et al. | T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. | 2015 | Anticancer Res. | pmid:26254411 |
| Piwko C et al. | Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. | 2015 | Clin Drug Investig | pmid:26123628 |
| Hayashi T et al. | Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. | 2015 | J. Urol. | pmid:26047983 |
| Shen BQ et al. | Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats. | 2015 | Drug Metab Lett | pmid:26031461 |
| Kan S et al. | Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. | 2015 | Oncol. Rep. | pmid:25976081 |
| Dholaria B and Srinivasan S | T-DM1-related carotenoderma and hand-foot syndrome. | 2015 | Lancet | pmid:25933279 |
| Li T et al. | Improvement of ansamitocin P-3 production by Actinosynnema mirum with fructose as the sole carbon source. | 2015 | Appl. Biochem. Biotechnol. | pmid:25564203 |
| Carneiro BA et al. | Emerging therapeutic targets in bladder cancer. | 2015 | Cancer Treat. Rev. | pmid:25498841 |
| Mang Y et al. | Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice. | 2015 | Int. Immunopharmacol. | pmid:25467246 |
| Kalsi R et al. | Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. | 2015 | Clin. Breast Cancer | pmid:25454740 |
| Sibaud V et al. | T-DM1-related telangiectasias: a potential role in secondary bleeding events. | 2015 | Ann. Oncol. | pmid:25403586 |
| Yamamoto H et al. | Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. | 2015 | Jpn. J. Clin. Oncol. | pmid:25332421 |
| Whiteman KR et al. | Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. | 2014 Mar-Apr | MAbs | pmid:24492307 |
| Tanz R et al. | [Towards an integrated approach to cardiovascular toxicities related to the treatments of breast cancer]. | 2014 Jul-Aug | Bull Cancer | pmid:25091656 |
| Panowski S et al. | Site-specific antibody drug conjugates for cancer therapy. | 2014 Jan-Feb | MAbs | pmid:24423619 |
| Beck A and Reichert JM | Antibody-drug conjugates: present and future. | 2014 Jan-Feb | MAbs | pmid:24423577 |
| Lieberman P and Castells M | Desensitization to chemotherapeutic agents. | 2014 Jan-Feb | J Allergy Clin Immunol Pract | pmid:24565784 |
| Bartsch R et al. | Breast cancer brain metastases responding to primary systemic therapy with T-DM1. | 2014 | J. Neurooncol. | pmid:24065570 |
| Ribrag V et al. | A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. | 2014 | Clin. Cancer Res. | pmid:24132920 |
| Krop I and Winer EP | Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. | 2014 | Clin. Cancer Res. | pmid:24135146 |
| Krop IE et al. | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. | 2014 | Lancet Oncol. | pmid:24793816 |
| Gnant M et al. | HER2-positive breast cancer: a new piece of the puzzle. | 2014 | Lancet Oncol. | pmid:24793817 |
| Wright J | Nanotechnology: Deliver on a promise. | 2014 | Nature | pmid:24870822 |
| Montemurro F | HER2 expression and efficacy of T-DM1. | 2014 | Breast Cancer Res. | pmid:25472666 |
| Leal M et al. | Antibody-drug conjugates: an emerging modality for the treatment of cancer. | 2014 | Ann. N. Y. Acad. Sci. | pmid:25123209 |
| Vigne E and Sassoon I | [The growing field of immunoconjugates in oncology. A successful link(er) between antibodies and small cytotoxic molecules]. | 2014 | Med Sci (Paris) | pmid:25311020 |
| Perrino E et al. | Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. | 2014 | Cancer Res. | pmid:24520075 |
| Feng L et al. | Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy. | 2014 | Clin. Cancer Res. | pmid:25294907 |
| Field JJ et al. | A previously undescribed tubulin binder. | 2014 | Proc. Natl. Acad. Sci. U.S.A. | pmid:25187564 |
| Torres S et al. | Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases. | 2014 | BMJ Case Rep | pmid:25123575 |
| Kümler I et al. | A systematic review of dual targeting in HER2-positive breast cancer. | 2014 | Cancer Treat. Rev. | pmid:24080156 |
| Prota AE et al. | A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. | 2014 | Proc. Natl. Acad. Sci. U.S.A. | pmid:25114240 |
| Berdeja JG | Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma. | 2014 | Front Biosci (Landmark Ed) | pmid:24389179 |
| Bender B et al. | A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. | 2014 | AAPS J | pmid:24917179 |
| Wang J et al. | Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. | 2014 | Clin. Pharmacol. Ther. | pmid:24488143 |
| Cretella D et al. | Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. | 2014 | Mol. Cancer | pmid:24898067 |
| Lianos GD and Roukos DH | From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer. | 2014 | Future Oncol | pmid:24490597 |
| English DP et al. | T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. | 2014 | Cancer Med | pmid:24890382 |
| Yan M et al. | HER2 aberrations in cancer: implications for therapy. | 2014 | Cancer Treat. Rev. | pmid:24656976 |
| Perez EA et al. | Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. | 2014 | Breast Cancer Res. | pmid:24887458 |
| Barok M et al. | Trastuzumab emtansine: mechanisms of action and drug resistance. | 2014 | Breast Cancer Res. | pmid:24887180 |
| Thery JC et al. | Resistance to human epidermal growth factor receptor type 2-targeted therapies. | 2014 | Eur. J. Cancer | pmid:24462377 |
| Tripathy D et al. | The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. | 2014 | BMC Cancer | pmid:24885258 |
| Amiri-Kordestani L et al. | FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. | 2014 | Clin. Cancer Res. | pmid:24879797 |
| Stinchcombe TE | Novel formulations and new mechanisms of delivering chemotherapy. | 2014 | Am Soc Clin Oncol Educ Book | pmid:24857128 |
| Welslau M et al. | Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. | 2014 | Cancer | pmid:24222194 |
| Golfier S et al. | Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. | 2014 | Mol. Cancer Ther. | pmid:24714131 |
| Diessner J et al. | Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). | 2014 | Cell Death Dis | pmid:24675467 |
| Gibiansky L and Gibiansky E | Target-mediated drug disposition model and its approximations for antibody-drug conjugates. | 2014 | J Pharmacokinet Pharmacodyn | pmid:24322877 |
| Carlson JA et al. | Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. | 2014 | Neuro-oncology | pmid:24497407 |
| Kim M et al. | Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer. | 2014 | Curr. Opin. Obstet. Gynecol. | pmid:24335887 |
| Miller KD et al. | Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. | 2014 | J. Clin. Oncol. | pmid:24733796 |
| Lu D et al. | Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. | 2014 | Cancer Chemother. Pharmacol. | pmid:24939213 |
| Villanueva MT | Targeted therapies: TH3RESA trial, overcoming hurdles in breast cancer. | 2014 | Nat Rev Clin Oncol | pmid:24913372 |
| Giordano SH et al. | Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. | 2014 | J. Clin. Oncol. | pmid:24799465 |
| Kusari S et al. | Endophytes are hidden producers of maytansine in Putterlickia roots. | 2014 | J. Nat. Prod. | pmid:25478947 |
| Fan Y et al. | Process optimization with alternative carbon sources and modulation of secondary metabolism for enhanced ansamitocin P-3 production in Actinosynnema pretiosum. | 2014 | J. Biotechnol. | pmid:25456055 |
| Coussy F et al. | [New targeted therapies in breast cancer]. | 2014 | Gynecol Obstet Fertil | pmid:25442825 |
| Bhardwaj AS et al. | A case of vasculitis in a breast cancer patient treated with T-DM1. | 2014 | Semin. Oncol. | pmid:25440614 |
| Mancuso L et al. | Preparation of thermocleavable conjugates based on ansamitocin and superparamagnetic nanostructured particles by a chemobiosynthetic approach. | 2014 | Chemistry | pmid:25346489 |
| Teplinsky E and Muggia F | Targeting HER2 in ovarian and uterine cancers: challenges and future directions. | 2014 | Gynecol. Oncol. | pmid:25220628 |
| Pillow TH et al. | Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. | 2014 | J. Med. Chem. | pmid:25191794 |
| Wada R et al. | Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. | 2014 | Cancer Chemother. Pharmacol. | pmid:25186956 |
| Hussar DA | New drugs 2014, part 3. | 2014 | Nursing | pmid:25153167 |
| White C | NICE confirms advanced breast cancer drug is too expensive for NHS. | 2014 | BMJ | pmid:25106642 |
| Corrigan PA et al. | Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. | 2014 | Ann Pharmacother | pmid:25082874 |
| Diéras V et al. | Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. | 2014 | J. Clin. Oncol. | pmid:25024070 |
| Yu L et al. | Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model. | 2014 | Int. J. Gynecol. Cancer | pmid:24987913 |
| Lambert JM and Chari RV | Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. | 2014 | J. Med. Chem. | pmid:24967516 |
| Sibaud V et al. | Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. | 2014 | Breast Cancer Res. Treat. | pmid:24929675 |
| Martin K et al. | The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. | 2014 | Cancer Immunol. Immunother. | pmid:24906866 |
| Kim MT et al. | Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. | 2014 | Bioconjug. Chem. | pmid:24873191 |
| Kolarich AR et al. | Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage. | 2014 | Acta Oncol | pmid:24834794 |
| Dhillon S | Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy. | 2014 | Drugs | pmid:24659374 |
| Patel KC et al. | Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. | 2014 | Am J Health Syst Pharm | pmid:24644113 |
| Diéras V and Bachelot T | The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. | 2014 | Target Oncol | pmid:23852665 |
| Boku N | HER2-positive gastric cancer. | 2014 | Gastric Cancer | pmid:23563986 |
| Gao Y et al. | Enhancement of ansamitocin P-3 production in Actinosynnema pretiosum by a synergistic effect of glycerol and glucose. | 2014 | J. Ind. Microbiol. Biotechnol. | pmid:24174216 |
| De Angelis C et al. | Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. | 2013 May-Jun | Tumori | pmid:24158083 |
| Sendur MA et al. | Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab? | 2013 Jul-Sep | J BUON | pmid:24065505 |
| Thudium K et al. | American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA. | 2013 Jan-Feb | MAbs | pmid:23255090 |
| Yaqub F | T-DM1 for HER2-positive metastatic breast cancer. | 2013 | Lancet Oncol. | pmid:23580966 |
| Hurvitz SA et al. | Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. | 2013 | J. Clin. Oncol. | pmid:23382472 |
| Ismaili N et al. | [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer]. | 2013 | Presse Med | pmid:23721860 |
| Wood AC et al. | Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. | 2013 | Pediatr Blood Cancer | pmid:23798344 |
| Zolot RS et al. | Antibody-drug conjugates. | 2013 | Nat Rev Drug Discov | pmid:23535930 |
| Traynor K | Ado-trastuzumab emtansine approved for advanced breast cancer. | 2013 | Am J Health Syst Pharm | pmid:23515502 |